Addex Therapeutics (ADXN) Gross Profit (2021 - 2025)

Addex Therapeutics has reported Gross Profit for 4 years, with the latest figure at -$4856.9 in Q2 2025.

• Quarterly Gross Profit changed N/A year-over-year to -$4856.9 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1.7 million (changed N/A YoY) and the FY2024 annual result came in at $439183.9, down 69.6% from the prior year.
• Gross Profit declined to -$4856.9 in Q2 2025 per ADXN's latest filing, from $580250.9 in the prior quarter.
• Over five years, Gross Profit peaked at $997126.4 in Q2 2021 and troughed at -$4856.9 in Q2 2025.
• A 4-year average of $414546.2 and a median of $332957.6 in 2022 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2022 and 2023: Gross Profit plunged 91.41% in 2022, then soared 577.35% in 2023.
• Over 4 years, Gross Profit stood at $997126.4 in 2021, then slumped by 91.41% to $85664.4 in 2022, then jumped by 577.35% to $580250.9 in 2023, then sank by 100.84% to -$4856.9 in 2025.
• According to Business Quant data, Gross Profit over the past three periods registered -$4856.9, $580250.9, and $85664.4 for Q2 2025, Q2 2023, and Q2 2022 respectively.